Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872170 · ClinicalTrials.gov registry record · Phase 2
Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
A Phase 2 study of Thalassemia and Hypertension, Pulmonary, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00872170 is a Phase 2 study of Thalassemia and Hypertension, Pulmonary that has completed, run by Carelon Research. The registered enrollment target is 27 participants, below the 89-participant average among 19 other Thalassemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00872170, a Phase 2 study of Thalassemia and Hypertension, Pulmonary, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Many people with thalassemia also have pulmonary hypertension, which is high blood pressure in the arteries in the lungs. This study will evaluate the safety and effectiveness of the medication sildenafil at reducing blood pressure in the lungs of people with thalassemia and pulmonary hypertension.
Conditions Studied
Interventions
- DRUG Sildenafil
Study Locations (1)
California
- Children's Hospital and Research Institute Oakland - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00872170
The ClinicalTrials.gov registry entry for NCT00872170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 19 other Thalassemia trials with a reported enrollment target (70% lower). The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which Sildenafil is the first listed.
NCT00872170 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00872170 about?
NCT00872170 is a clinical study titled "Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension". Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Many people with thalassemia also have pulmonary hypertension, which is high blood pressure in the arteries in the lungs. This study will evaluate the safety and effectiveness of the medication sildenafil at reducin...
What is the current status of trial NCT00872170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-03. Estimated completion is 2010-11.
What conditions does trial NCT00872170 study?
This clinical trial studies the following conditions: Thalassemia, Hypertension, Pulmonary.
What interventions are being tested in trial NCT00872170?
The interventions under investigation include: Sildenafil (DRUG).
Who is sponsoring clinical trial NCT00872170?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00872170 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
COMPLETED · Phase 2
-
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
COMPLETED · Phase 2
-
Stem Cell Transplant for Hemoglobinopathy
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.